Literature DB >> 34315516

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology.

Xiao-Fang Yang1, Ming Lu2, Lijiao You1, Huan Gen1, Lin Yuan1, Tianning Tian2, Chun-Yu Li3, Kailiang Xu4, Jie Hou5, Ming Lei6.   

Abstract

The worldwide prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, and this metabolic disorder has been recognized as a severe threat to human health. A variety of chemical drugs have been approved for treating NAFLD, however, they always has serious side effects. Chinese herbal medicines (CHMs) have been widely used for preventing and treating a range of metabolic diseases with satisfactory safety and effective performance in clinical treatment of NAFLD. Recent studies indicated that imbanlance of the intestinal microbiota was closely associated with the occurrence and development of NAFLD, thus, the intestinal microbiota has been recognized as a promising target for treatment of NAFLD. In recent decades, a variety of CHMs have been reported to effectively prevent or treat NAFLD by modulating intestinal microbiota to further interfer the gut-liver axis. In this review, recent advances in CHMs for the treatment of NAFLD via rebuilding the intestinal microecology were systematically reviewed. The key roles of CHMs in the regulation of gut microbiota and the gut-liver axis along with their mechanisms (such as modulating intestinal permeability, reducing the inflammatory response, protecting liver cells, improving lipid metabolism, and modulating nuclear receptors), were well summarized. All the knowledge and information presented here will be very helpful for researchers to better understand the applications and mechanisms of CHMs for treatment of NAFLD.
© 2021. The Author(s).

Entities:  

Keywords:  Chinese herbal medicines (CHMs); Gut microbiota; Gut-liver axis; Intestinal microecology; Nonalcoholic fatty liver disease (NAFLD)

Year:  2021        PMID: 34315516     DOI: 10.1186/s13020-021-00470-x

Source DB:  PubMed          Journal:  Chin Med        ISSN: 1749-8546            Impact factor:   5.455


  67 in total

1.  The gut-liver axis in nonalcoholic fatty liver disease: Another pathway to insulin resistance?

Authors:  Ester Vanni; Elisabetta Bugianesi
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

Review 2.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

3.  Ferulic acid ameliorates nonalcoholic fatty liver disease and modulates the gut microbiota composition in high-fat diet fed ApoE-/- mice.

Authors:  Yunci Ma; Kai Chen; Lin Lv; Shaoyu Wu; Zhijian Guo
Journal:  Biomed Pharmacother       Date:  2019-03-09       Impact factor: 6.529

4.  Gut microbiota dysbiosis correlates with a low-dose PCB126-induced dyslipidemia and non-alcoholic fatty liver disease.

Authors:  Yulang Chi; Yi Lin; Yanyang Lu; Qiansheng Huang; Guozhu Ye; Sijun Dong
Journal:  Sci Total Environ       Date:  2018-10-30       Impact factor: 7.963

5.  An obesity-associated gut microbiome with increased capacity for energy harvest.

Authors:  Peter J Turnbaugh; Ruth E Ley; Michael A Mahowald; Vincent Magrini; Elaine R Mardis; Jeffrey I Gordon
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

Review 6.  Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.

Authors:  Ruiting Han; Junli Ma; Houkai Li
Journal:  Front Med       Date:  2018-09-04       Impact factor: 4.592

Review 7.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

Review 8.  Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.

Authors:  Yan-Yan Ma; Lin Li; Chao-Hui Yu; Zhe Shen; Li-Hua Chen; You-Ming Li
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

Review 9.  Treatment of nonalcoholic steatohepatitis in adults: present and future.

Authors:  S Gitto; G Vitale; E Villa; P Andreone
Journal:  Gastroenterol Res Pract       Date:  2015-03-18       Impact factor: 2.260

Review 10.  Herbal drug discovery for the treatment of nonalcoholic fatty liver disease.

Authors:  Tingting Yan; Nana Yan; Ping Wang; Yangliu Xia; Haiping Hao; Guangji Wang; Frank J Gonzalez
Journal:  Acta Pharm Sin B       Date:  2019-12-10       Impact factor: 11.413

View more
  1 in total

1.  Gut Microbiota Modulates the Protective Role of Ginsenoside Compound K Against Sodium Valproate-Induced Hepatotoxicity in Rat.

Authors:  Luping Zhou; Xiangchang Zeng; Jianwei Liao; Lulu Chen; Dongsheng Ouyang
Journal:  Front Microbiol       Date:  2022-07-07       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.